Solifenacin succinate + Mirabegron + Placebo to match solifenacin + Placebo to match mirabegron
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Bladder Overactive
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Trial Timeline
Mar 17, 2014 → Sep 8, 2016
NCT ID
NCT02045862About Solifenacin succinate + Mirabegron + Placebo to match solifenacin + Placebo to match mirabegron
Solifenacin succinate + Mirabegron + Placebo to match solifenacin + Placebo to match mirabegron is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT02045862. Target conditions include Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence.
What happened to similar drugs?
8 of 20 similar drugs in Urinary Bladder Overactive were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02045862 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Bladder Overactive